UCB Pharma (UCB)

Executive Summary

UCB Pharma is a Belgian biopharmaceutical leader in severe neurological and autoimmune diseases, with a portfolio including established epilepsy therapies (Keppra, Vimpat, Briviact) and the autoimmune drug Cimzia. The company is transitioning to a growth phase driven by recent launches such as Bimzelx (bimekizumab) for psoriasis and novel assets like rozanolixizumab and zilucoplan for generalized myasthenia gravis. UCB's pipeline includes late-stage candidates targeting high unmet needs, but it faces revenue pressure from generic erosion of older products. The company's strong R&D focus on differentiated biologics and small molecules positions it for sustained innovation, though execution risks remain in competitive landscapes. Near-term catalysts include regulatory decisions and pivotal data readouts that could drive significant upside.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on rozanolixizumab for generalized myasthenia gravis70% success
• Q2 2026Phase 3 results for bimekizumab in hidradenitis suppurativa60% success
• Q4 2026EU approval decision for zilucoplan in generalized myasthenia gravis80% success